Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of…
Revenue expected to be between $195 and $205 million, represents a 31% to 38% increase over the midpoint of 2023…
iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain Phase…
Dr. Adi Hoess to step down as CEO and Management Board MemberDr. Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount…
Leading Investors BOLD Capital, Digitalis Ventures, and Hill Creek Partners drive financial milestone Financing to expedite conditional FDA approval of…
Combined organizations have helped more than 1 million kids Expands Specialty Bracing Division with pediatric orthotic management business offering leading technology…
MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the…
Complete enrollment in Denali-led, late-stage programs for MPS II and ALS, and establish commercial readinessAdvance broad clinical-stage portfolio of seven…
HORSHAM, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology…
Partnership aims to include Aclarion’s surgical decision support technology within ATEC’s AlphaInformatiX platform to better inform spine surgery Aclarion’s Nociscan…